These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31270031)

  • 1. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction.
    van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP
    Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.
    Sherazi S; Shah F; Kutyifa V; McNitt S; Aktas MK; Polonsky B; Zareba W; Goldenberg I
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1172-1181. PubMed ID: 31648742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function.
    Galve E; Oristrell G; Acosta G; Ribera-Solé A; Moya-Mitjans À; Ferreira-González I; Pérez-Rodon J; García-Dorado D
    Clin Cardiol; 2018 Jun; 41(6):803-808. PubMed ID: 29604094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
    Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R
    ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure.
    Biton Y; Rosero S; Moss A; Zareba W; Kutyifa V; Baman J; Barsheshet A; McNitt S; Polonsky B; Goldenberg I
    Am J Cardiol; 2018 Mar; 121(5):615-620. PubMed ID: 29307459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification.
    Providência R; Boveda S; Defaye P; Segal O; Algalarrondo V; Sadoul N; Lambiase P; Piot O; Klug D; Perier MC; Bouzeman A; Barra S; Bories MC; Gras D; Fauchier L; Bordachar P; Babuty D; Deharo JC; Leclercq C; Marijon E;
    Am J Cardiol; 2016 Oct; 118(8):1225-1232. PubMed ID: 27561197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
    Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM
    JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy.
    Gronda E; Genovese S; Padeletti L; Cacciatore F; Vitale DF; Bragato R; Innocenti L; Schiano C; Sommese L; De Pascale MR; Genovese L; Abete P; Donatelli F; Napoli C
    Cardiol J; 2015; 22(4):459-66. PubMed ID: 26325259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only.
    Palmisano P; Accogli M; Pisanò EC; Zaccaria M; De Blasi S; Ponzetta MA; Valsecchi S; Milanese G; Lauretti M; Magliari F
    Europace; 2016 Sep; 18(9):1374-82. PubMed ID: 26612878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients.
    Zhang Y; Guallar E; Blasco-Colmenares E; Butcher B; Norgard S; Nauffal V; Marine JE; Eldadah Z; Dickfeld T; Ellenbogen KA; Tomaselli GF; Cheng A
    J Am Coll Cardiol; 2015 Aug; 66(5):524-31. PubMed ID: 26227190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.